Carlemi Calitz

Carlemi is a UPC legal officer and patent advisor of the Intellectual Property practice group.

She brings a uniquely multidisciplinary perspective to the Patents and Innovation team, combining over a decade of cutting-edge scientific research with a growing legal expertise. As a UPC Legal Officer with a focus on patent advisory, she draws on her extensive background in pharmaceutics, biochemistry, and advanced biomimetic modeling to support clients at the intersection of science, technology, and intellectual property.

With 27 peer-reviewed publications and experience in managing EU-funded innovation projects, she is adept at navigating complex scientific and regulatory landscapes—an asset in evaluating patentability, supporting IP strategy, and communicating effectively with inventors and examiners.

CV

Since 2025 UPC Legal Officer, Taylor Wessing

2021-2025 Postdoctoral Research Fellow GUTVIBRATIONS consortium, Amsterdam UMC

2018-2021 Postdoctoral Research Fellow, Uppsala University, Sweden

Karriere

Since 2025 UPC Legal Officer, Taylor Wessing

2021-2025 Postdoctoral Research Fellow GUTVIBRATIONS consortium, Amsterdam UMC

2018-2021 Postdoctoral Research Fellow, Uppsala University, Sweden

Ausbildung

2017 PhD Pharmaceutics, North west University

2014 MSc Pharmaceutics, North-west University

2011 Hons. BSc Biochemistry and Physiology, North-west University

Publikationen

Effect of antivirals on clinical and lab-adapted human cytomegalovirus strains using induced Pluripotent Stem Cell-derived human neural models. 2025. L Mulder, R Vieira da Sá, J Korsten, E Freeze, G Koen, R Molenkamp, J Van Kampen, M Cornelissen, F Zorgdrager, KC Wolthers, D Pajkrt, A Sridhar and C Calitz. Submitted to Antiviral Research.
Towards personalized medicine: the effect of treatment of chronic enterovirus diarrhea in an immunocompromised patient and the correlation with in vitro models. 2024. G Moreni, C Calitz, G Koen, H van Eijk, N Johannesson, J De Ruijter, K S M Benschop, J Cremer, D Pajkrt, A Sridhar, E J Peters, and K C Wolthers. Submitted to Open Forum Infectious Diseases (Under review)
A Human Biomimetic Intestinal Mucosa Model to Study Gastrointestinal Development and Disease. 2024. A Dei*, C Calitz*, J Korsten, N Johannesson, E Freeze, A Eaves, S Louis, R.K. Conder, W Chang, D Pajkrt, K.C. Wolthers, A Sridhar, S Simmini. Submitted to Nature Communications. https://doi.org/10.1101/2024.08.20.608742 *Shared first authorship
Parechovirus infection in human brain organoids: host innate inflammatory response and not neuro-infectivity correlates to neurologic disease. 2024. P Capendale, I García-Rodríguez, AT Ambikan, L Mulder, J Depla, E Freeze, G Koen, C Calitz, V Sood, R Vieira de Sá, U Neogi, D Pajkrt, A Sridhar and K Wolthers. Nature Communications 15(1):2532. 10.1038/s41467-024-46634-9.
The combination of pleconaril, rupintrivir, and remdesivir efficiently inhibits enterovirus infections in vitro, delaying the development of drug-resistant virus variants. 2024. Ianevski A, Frøysa, IT, Lysvand, H, Calitz, C, Smura, T, Schjelderup Nilsen, H.-J, Høyer, E, Afset, JE, Sridhar, A, Wolthers, KC, Zusinaite, E, Tenson, T, Kurg, R, Oksenych, V, Galabov, AS, Stoyanova, A, Bjørås, M and Kainov, DE. Antiviral Research. https://doi.org/10.1016/j.antiviral.2024.105842
Assessment of The Broad-Spectrum Host Targeting Antiviral Efficacy of Halofuginone Hydrobromide in Human Airway, Intestinal and Brain Organoid Models. 2024. I García-Rodríguez, G Moreni, P.E Capendale, I Aknouch, L Mulder, R Vieira de Sá, N Johannesson, E Freeze, H van Eijk, G Koen, K.C Wolthers, D Pajkrt, A Sridhar and C Calitz Antiviral Research https://doi.org/10.1016/j.antiviral.2024.105798 *Shared last authorship
Non-Polio Enterovirus C Replicate in Both Airway and Intestine Organotypic Cultures. 2023
G Moreni, H van Eijk, G Koen, N Johannesson, C Calitz, K Benschop, J Cremer, D Pajkrt, A Sridhar and K Wolthers Viruses 15(9):1823
Amino acid variation at VP1-145 of enterovirus A71 determines the viral infectivity and receptor usage in a primary human intestinal model. 2023. I Aknouch, I García-Rodríguez, F.P Giugliano, C Calitz, G Koen, H van Eijk, N Johannessson, S Rebers, L Brouwer, V Muncan, KJ Stittelaar, D Pajkrt, K.C Wolthers and A Sridhar Frontiers in Microbiology 14:1045587
Influence of extracellular matrix composition on tumour cell behaviour in a biomimetic in vitro model for hepatocellular carcinoma. 2023. C Calitz, J Rosenquist, O Degerstedt, J Khaled, M Kopsida, M Fryknäs, H Lennernäs, A Samanta, F Heindryckx. Scientific Reports 13(1):748
Human milk inhibits some enveloped virus infections, including SARS-CoV-2, in an intestinal model. 2022. Aknouch, I., Sridhar, A., Freeze, E., Giugliano, F.P., van Keulen, B.J., Romijn, M., Calitz, C., García-Rodríguez, I., Mulder,L., Wildenberg, M.E., Muncan, V., van Gils, M.J., van Goudoever, J.B., Stittelaar, K.J., Wolthers, K.C and Pajkrt, D. Life science alliance., 5(12): e202201432
Effect of liver stiffness on hepatocellular carcinoma phenotype in a biometric 3D model. 2022. C Calitz, J Khaled, J Rosenquist, M Kopsida, O Degerstedt, H Lennernas, M Fryknäs, A Samanta and F Heindryckx. Journal of Hepatology., 77:s368

Bridging the gap between emerging models and humans by learning from polio animal studies: A systematic review. 2022. G Moreni, I Aknouch, M Ras, L Brouwer, R Spijker, C Calitz, KJ Stittelaar, A Sridhar, KC Wolthers, D Pajkrt. Clinical and Translational Discovery., 2(2):e42
In vitro cell toxicity and intracellular uptake of doxorubicin exposed as a solution or liposomes: Implications for treatment of hepatocellular carcinoma. 2021. F Kullenberg, O Degerstedt, C Calitz, N Pavlović, D Balgoma, J Gråsjö, E Sjögren, M Hedeland, F Heindryckx, H Lennernäs. Cells., 10(7):1717
Anthracyclins increase PUFAs: potential implications in ER stress and cell death. 2021.
D Balgoma, F Kullenberg, C Calitz, M Kopsida, F Heindryckx, H Lennernäs, M Hedeland. Cells., 10(5):1163
Clinostat 3D cell culture – protocols for the preparation and functional analysis of highly reproducible, large, uniform spheroids and organoids. 2021. K Wrzesinski, H Sedighi-Frandsen, C Calitz, C Gouws, B Korzeniowska, SJ. Fey. Next Generation Culture Platforms for Reliable In Vitro Models: Methods and Protocols, Chapter 2: 17-62
Anticancer Potential of Sutherlandia frutescens and Xysmalobium undulatum in LS180 Colorectal Cancer Mini-Tumors. 2021. C Gouws, T Smit, C Willers, H Svitina, C Calitz, K Wrzesinski. Molecules 26(3):605
Inhibiting endoplasmic reticulum stress decreases tumor burden in a mouse model for hepatocellular carcinoma. 2020. N Pavlovic, C Calitz, K Thanapirom, G Mazza, K Rombouts, P Gerwins, F Heindryckx. eLife, 9, e55865
A Biomimetic Model for Liver Cancer to Study Tumor-Stroma Interactions in a 3D. 2020. C Calitz, N Pavlovic, J Rosenquist, C Zagami, A Samanta, F Heindryckx. J. Vis. Exp. (162), e61606
Characterization of an alginate encapsulated LS180 spheroid model for anti-colorectal cancer compound screening. 2020. T Smit, C Calitz, C Willers, H Svitina, J Hamman, SJ Fey, C Gouws, K Wrzesinski. ACS Medicinal Chemistry Letters 11 (5), 1014-1021
Fibrin fragment E potentiates TGF-β-induced myofibroblast activation and recruitment. 2020. PÖ Fuchs, C Calitz, N Pavlović, F Binet, SMØ Solbak, UH Danielson, J Kreuger, F Heindryckx, P Gerwins. Cellular Signalling, 109661
A sub-chronic Xysmalobium undulatum hepatotoxicity investigation in HepG2/C3A spheroid cultures compared to an in vivo model. 2019. C Calitz, JH Hamman, SJ Fey, AM Viljoen, C Gouws, K Wrzesinski. Journal of Ethnopharmacology 239, 111897
Toxicity and anti-prolific properties of Xysmalobium undulatum water extract during short-term exposure to two-dimensional and three-dimensional spheroid cell. 2018. C Calitz, JH Hamman, AM Viljoen, SJ Fey, K Wrzesinski, C Gouws Toxicology mechanisms and methods 28 (9), 641-652
Recent Advances in Three-Dimensional Cell Culturing to Assess Liver Function and Dysfunction: From a Drug Biotransformation and Toxicity Perspective. 2018. C Calitz, JH Hamman, SJ Fey, K Wrzesinski, C Gouws Toxicology Mechanisms and Methods, 1-17
Cell-free DNA in a three-dimensional spheroid cell culture model: A preliminary study. 2017.
C Calitz*, J Aucamp*, AJ Bronkhorst, K Wrzesinski, S Hamman, C Gouws. The international journal of biochemistry & cell biology 89, 182-192 *Shared first authorship
Herb-drug pharmacokinetic interactions: transport and metabolism of indinavir in the presence of selected herbal products. 2015. C Calitz, C Gouws, J Viljoen, J Steenekamp, L Wiesner, E Abay. Molecules 20 (12), 22113-22127
Herbal hepatotoxicity: current status, examples, and challenges. 2015. C Calitz, L Du Plessis, C Gouws, D Steyn, J Steenekamp, C Muller. Expert opinion on drug metabolism & toxicology 11 (10), 1551-1565
Impact of traditional African medicine on drug metabolism and transport. 2014. C Calitz, JH Steenekamp, JD Steyn, C Gouws, JM Viljoen, JH Hamman Expert opinion on drug metabolism & toxicology 10 (7), 991-1003

Mitgliedschaften

The Pharmaceutical society of South Africa PSSA

Dr. Carlemi Calitz

Expertise

Rechtsgebiete und Gruppen

Branchen

CV

Karriere

Ausbildung

Publikationen

Mitgliedschaften

Fremdsprachen

Dr. Carlemi Calitz

Expertise

Rechtsgebiete und Gruppen

Branchen

CV

Karriere

Ausbildung

Publikationen

Mitgliedschaften

Fremdsprachen

Aktuelle News & Insights

Dual Use Technologies in Biotech and their Regulation in the EU and Germany

Preliminary injunctions in the UPC – lessons learnt

Two years of UPC patent litigation: key lessons for life sciences companies

UPC litigation in life sciences: seven early takeaways for the pharma, biotech and medical devices sectors

Revocation of life sciences patents in the UPC

The UPC going beyond its borders: how your company can profit from the latest case law

UPC patent infringement: recent updates for the life sciences sector

Advertising skinny jabs – regulators react

Taylor Wessing im Handelsblatt Ranking 2025

What have we learned from two years UPC preliminary injunctions?

Weitere Beraterinnen und Berater

Meet me at